Dr. Lim's primary research interest involves immune-based therapies against brain tumors. His research focuses on understanding the mechanisms of immune evasion by primary brain tumors with the goal of translation to novel therapies against gliomas. Dr. Lim also performs clinical research. He publishes extensively in radiosurgery and also has interests in brain tumor clinical trials for which he works closely with the neuro-oncologists in a team approach.
Dr. Lim is the Director of the Brain Cancer Immunology Laboratory at Johns Hopkins. His laboratory explores mechanisms of immune resistance and novel therapies for brain tumors. In addition, his laboratory performs translational studies to develop the next generation of clinical trials.
Dr. Lim is the co-principal investigator of the Johns Hopkins Comprehensive Subependymoma and Ependymoma Research Center. This research center conducts basic science, translational and clinical practice research with the goals of optimizing current treatment options and developing new therapies that will positively impact the care and lives of patients with subependymomas and ependymomas, primary central nervous system (CNS) brain tumors
Clinical Trial Keywords
EGFRvIII, Vaccine, Oncophage
STUDY NAME: SRS (Stereotactic Radiosurgery) Plus Ipilimumab
- SUMMARY: This research is being done to look at the safety of using stereotactic radiosurgery (SRS) and Ipilimumab together to treat melanoma that has spread to the brain or spine. Both Ipilimumab and SRS are used alone for the treatment of melanoma that has spread. Standard of care uses both of these treatments but are not at the same time. By using them together, we expect better treatment of melanoma, but there might be an increase in side effects. This research study plans to look at the timing and sequence of the SRS and the Ipilumumab. There is also an option to adjust the doses of the Ipilumumab if too many side effects are seen. Ipilimumab is approved by the Food and Drug Administration (FDA) for the treatment of melanoma that has spread throughout the body. It works by activating your immune system to fight off cancer. Stereotactic radiosurgery (SRS) is approved by the FDA for the treatment of melanoma in the brain or spine. It uses radiation to treat tumors without needing to cut or use stitches. The combination of SRS and Ipilimumab in this research study is investigational. The word "investigational" means that this combination is not approved by the FDA.
STUDY NAME: A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)
- SUMMARY: The purpose of the study is to understand the safety, tolerability and efficacy of Nivolumab as a single agent or in combination with Ipilimumab versus Bevacizumab in patients diagnosed with Recurrent Glioblastoma (GBM).
View all on Pubmed
Carboxylated Branched Poly(β-amino ester) Nanoparticles Enable Robust Cytosolic Protein Delivery and CRISPR-Cas9 Gene Editing. Rui Y, Wilson DR, Choi J, Varanasi M, Sanders K, Karlsson J, Lim M, Green JJ. Sci Adv. 2019 Dec 6;5(12):eaay3255
Herrmann A, Lahtz C, Song J, Aftabizadeh M, Cherryholmes GA, Xin H, Adamus T, Lee H, Grunert D, Armstrong B, Chu P, Brown C, Lim M, Forman S, Yu H. Oncogene. 2019 Dec 9
PD-L1 Expression in Pediatric Low-Grade Gliomas is Independent of BRAF V600E Mutational Status. Martin AM, Bell WR, Yuan M, Harris L, Poore B, Arnold A, Engle EL, Asnaghi L, Lim M, Raabe EH, Eberhart CG. J Neuropathol Exp Neurol. 2019 Dec 9
In vivo Bioluminescence Tomography Center of Mass-Guided Conformal Irradiation. Deng Z, Xu X, Garzon-Muvdi T, Xia Y, Kim E, Belcaid Z, Luksik A, Maxwell R, Choi J, Wang H, Yu J, Iordachita I, Lim M, Wong JW, Kang-Hsin Wang K. Int J Radiat Oncol Biol Phys. 2019 Nov 15
Anti-PD-1 Mediated Anti-Tumor Immune Response in GBM is Enhanced by Local Chemotherapy and Abrogated by Systemic Chemotherapy. Mathios D, Kim J, Mangraviti A, Phallen J, Park CK, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M, Martin AM, Suk I, Ye X, Tyler B, Bettegowda C, Brem H, Pardoll DM, Lim M. Sci Transl Med. 2016 Dec 21;8(370):370ra180